Oral Probenecid for Nonhospitalized Adults with Symptomatic Mild-to-Moderate COVID-19

Probenecid is an orally bioavailable, uricosuric agent that was first approved in 1951 for the treatment of gout, but was later found to have potent, broad-spectrum antiviral activity against several respiratory viruses including SARS-CoV-2. We conducted a phase 2 randomized, placebo-controlled, sin...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin, David E., Pandey, Neelam, Chavda, Purvi, Singh, Gurpreet, Sutariya, Rakesh, Sancilio, Frederic, Tripp, Ralph A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386418/
https://www.ncbi.nlm.nih.gov/pubmed/37515194
http://dx.doi.org/10.3390/v15071508

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386418/
https://www.ncbi.nlm.nih.gov/pubmed/37515194
http://dx.doi.org/10.3390/v15071508

Ejemplares similares